Key facts
- Lumiere Therapeutics’s last known valuation is $33.4M (Dec 2021).
- It has raised $11.8M; the latest was Early Stage VC in Jan 2025.
- Notable investors include Apricot Capital (Shanghai), FC Innovation Venture Fund, Guangzhou Industrial Investment Holding Group.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Lumiere Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Lumiere Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Lumiere Therapeutics
Developer of human genetic diagnosis and therapy designed for Biotechnology. The company focuses on developing gene editing tools, delivery tools, and related products, enabling patients to relief their pain, recreate immunity, and delay the debilitating aging of organs.
- Sector
- Healthcare
- HQ
- Suzhou, China
- Founded
- 2021
- Employees
- 10
- Website
- ltcure.com/
- Ownership
- Privately Held (backing)
Lumiere Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Lumiere Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Lumiere Therapeutics in its N-PORT filings yet. We sweep new filings monthly.